|Bid||35.81 x 1200|
|Ask||36.43 x 1300|
|Day's Range||35.75 - 36.33|
|52 Week Range||29.83 - 36.60|
|PE Ratio (TTM)||26.48|
|Dividend & Yield||1.28 (3.52%)|
|1y Target Est||N/A|
Reckitt Benckiser has decided to split its business into two units - consumer healthcare and home and hygiene products - the British consumer goods company said on Wednesday, after warning that there would be no growth in sales this year. Reckitt said to help boost performance it would operate from two business units from the start of 2018. Chief Executive Rakesh Kapoor told Reuters the restructuring decision was made after the acquisition in June of baby milk maker Mead Johnson, its biggest ever acquisition.
Reckitt Benckiser (RB.L) plans to reorganise its business into two distinct units, one for health and the other for hygiene and home products, as it tries to improve its flagging performance. The maker of Durex condoms, Nurofen tablets and Dettol cleaners announced the restructuring on Wednesday, along with its third-quarter sales figures. The British company made the decision to restructure after its June acquisition of U.S. baby formula maker Mead Johnson, which will account for roughly half of the larger health unit's sales.
Reckitt Benckiser Group Plc separated its home-care and health businesses as Chief Executive Officer Rakesh Kapoor pins hopes for growth on brands such as Durex condoms and Enfamil baby formula after a ...
Results of a 32-patient study of a drug made by Ignyta Pharmaceuticals, a San Diego-based drugmaker, are a best case scenario for the company. The drug shrank tumors in 79% of patients and kept workingabout 10 months longer than the current drug, Pfizer’s Xalkori, did in earlier clinical trials.
Shares of Aerie Pharmaceuticals, Inc. (AERI) have moved up 15.8% in the last week on positive news for its lead drug, Rhopressa.
The quest for the “holy grail” of cardiovascular therapy - a drug that dramatically lowered LDL-c and raised HDL-c and which would hopefully reverse atherosclerosis - has ended ignominiously.
The pharmaceutical industry puts the cost of bringing a medicine from invention to pharmacy shelves at $2.7 billion. A new paper says it is 'just' $648 million. Unfortunately for pharmaceutical investors and people fighting to control drug prices, alike, the new number doesn’t stand up scrutiny.
Customers may be starting to shop for over-the-counter drugs in the same way they shop for groceries—with a keener eye for cost and content—and this could be painful for consumer-health companies.
A deal would give the company capital to do more deals but the decision also keeps the company's recently scratched plans to split into two separate companies alive. The division itself had about $3.4 ...
So far in October, of the 22 analysts covering Eli Lilly (LLY), four have suggested a “strong buy,” while ten analysts have suggested a “buy.”
Pharmaceutical third-quarter earnings are nearly upon us, and Guggenheim's Tony Butler and Allen Cha provide their thoughts on the upcoming results. Butler and Cha write that the hurricanes are a factor ...
T here’s been speculation about whether or not Pfizer (PFE) is planning to make a large acquisition, and Guggenheim’s Tony Butler takes on the question, writing that a smart deal could expand the pharma giant’s multiple. Butler notes that Pfizer’s management has stated that it’s aware of the need to create shareholder value, and he believes that the outcome hinges on a number of factors, including any potential tax reform/cash repatriation holiday, as well as clinical trial results. At the moment, Pfizer has a joint venture with Merck (MRK) to develop Bavencio, a PD-L1 antibody, but Butler wonders if it might be willing to step back if the data isn’t supportive, and if it might be willing to acquire a company with a different, PD-1 antibody—again if the data bears it out.
Pfizer (PFE) is looking at strategic options for its Consumer Healthcare business while Merck announced that it won't be seeking approval for its CETP inhibitor.
Markets barely reacted when Gilead Sciences Inc. (NASDAQ:GILD) announced on Sept. 14 that it would buy Kite Pharma, Inc. for $11.9 billion. The slowdown in Gilead’s HCV business is starting to come to an end. The HCV segment will continue adding meaningfully to Gilead’s cash flow, which is money it needs to fund the Kite acquisition.
First, it raised some spinoff speculation. Second, it's in an intriguing tussle with J&J that could affect the biosimilars market for everyone.
Credit Suisse We are not surprised by Pfizer’s announcement [Tuesday] morning that they are exploring strategic options for their Consumer Healthcare business. Based on our recent conversations with the company, it had become clear to us that Pfizer (PFE) management does not see this business as part of their long-term innovative core. After speaking with the company again today and based on their previous transactions, we assume Pfizer will take their usual time and care in exploring all options.